ong–term Analysis of DImethyl fumarate, to slow the Growth of Areas of Geographic Atrophy

Phase 1

• Conditions: Macular degeneration; Therapeutic area: Diseases [C] - Eye Diseases [C11]

• Registration Number: CTIS2024-510741-33-00
• Lead Sponsor: Assistance Publique Hopitaux De Paris

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-21
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Age 55 years of age to 85 years old at the moment of inclusion, Participant must understand and sign the protocol's informed consent document, Participant must have central or non-central geographic atrophy (GA) in at least one eye. GA should be at least 0.75 disk areas (DA) in size but no more than 8 disk areas (DA); approximately 2.54 mm2 is 1 DA, Participant must have a steady fixation in the study eye in the foveal or parafoveal area and media clear enough for good quality photographs, Participant must have visual acuity between 20/20 and 20/200 in the affected eye, No suggestive sign of progressive multifocal leukoencephalopathy on brain MR Imaging within 3 months of Dimethyl Fumaratetreatment Initiation (Only the patients randomized in the Dimethyl FumarateGroup will have to go through the MR Imaging), Male participants with female partners capable of conceiving children will be required to use contraception (condom) during the study and for four months after their last experimental treatment caps, No documented history of heart disease, absence of family history of sudden death, and QTc duration within normal value (<480ms), Participants must be affiliated to a social security scheme

Exclusion Criteria

Participant is in another interventional investigational study < 3 months before inclusion, Participant is on chronic (more than 3 months) immunosuppressive medication administered via ocular or systemic route(s) or is immunosuppressed, Participant is on ocular or systemic medications known to be toxic to the lens, retina or optic nerve, Participant with a history of malignancy that would compromise the 2-year study survival, Participant with a history of ocular herpes simplex virus (HSV), Contra-indications or known hyper-sensibility to Dimethyl Fumarate or experimental treatment excipients, Severe active gastrointestinal disease, Contra-indications to an MRI using gadolinium such as pace maker, cardiac valve non IRM compatible, cochlear implant or any metallic implant non IRM compatible, Any contraindications to gadolinium including pregnancy, previous allergic reaction, severe kidney disease, Any contraindications to aspirin, Any screening laboratory value (hematology, serum chemistry or urinalysis) 3 times above normal values or that in the opinion of the Investigator is clinically significant and not suitable for study participation, Participant is unable to comply with study procedures or follow-up visits, Lymphopenia: below normal laboratory values at inclusion, Severe impairment of a vital organ including severe liver and renal impairment, Previous organ allograft, Patients taking the following non-authorized treatment 3 months prior enrolment: other fumaric acid derivatives (topical (ocular) or systemic), immuno-modulators via ocular or systemic routes (including interferons, sirolimus, chronic use of glucocorticoids), cytotoxic treatments and live attenuated vaccines.(NB: During the experimental treatment period and 3 months thereafter the concomitant use of non-authorized treatment cited above is not allowed in patients randomized in the Dimethyl Fumarate group), Patients taking the following non-authorized treatment 3 months prior enrolment: nephrotoxic treatment (aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs (via ocular or systemic routes) or lithium). (NB: During the experimental treatment period and 3 months thereafter the concomitant use of non-authorized nephrotoxic treatment cited above is not allowed in patients randomized in the Dimethyl Fumarate group), Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control), History of cancer (other than a non-melanoma skin cancer) diagnosed within the past five years that could be worsened by immunosuppression(In case of history of cancer the risk of immunosuppression must be determined by a specific oncology consultation prior to enrollment.), Ocular or peri-ocular inflammation or infection in either eye, Presence of active or inactive toxoplasmosis in any or both eye(s), Presence of active or latent tuberculosis infection, Participant has evidence of ocular disease other than GA in either eye that may confound the outcome of the study (e.g., glaucoma, diabetic retinopathy with 10 or more hemorrhages or micro-aneurysms, uveitis, pseudo-vitelliform macular degeneration, exudative macular degeneration, moderate/severe myopia), Female participants of childbearing potential (those who are not post-menopausal or surgically sterile). Postmenopausal state is 12 months of amenorrhea + high level of FSH if required, Persons under curatorship or guardia

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified